Introduction
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Correct nodal staging depends on multiple factors, including number of examined nodes [3] . Moreover, occult tumor cells and micrometastases are easily missed by conventional histopathologic examination. Various retrospective studies have shown poor prognosis for patients with micrometastases compared with patients without metastases [4, 5] . Multiple clinical trails are currently ongoing in which patients with micrometastatic disease are treated with adjuvant chemotherapy, which is currently not considered for this indication [6] . However, detection of micrometastases often requires ultrastaging techniques for each lymph node using serial sectioning and additional immunohistochemistry or reverse transcriptaseepolymerase chain reaction [7, 8] . However, this is currently beyond standard histopathologic analysis and is timeconsuming, and expensive. To overcome this disadvantage, the sentinel lymph node (SLN) procedure for colon cancer patients has been evaluated extensively [9] .
Sentinel lymph node are the first lymph nodes that receive lymphatic drainage from the tumor, and identification of the SLN and analysis for tumor involvement could predict the tumor status of the remaining lymph nodes. Therefore, the SLN procedure in colon cancer can be a useful tool to select the nodes for ultrastaging [4] . In colon cancer patients, both blue dyes and radiotracers have been used as SLN tracers in an in vivo and ex vivo setting [9] . However, both have disadvantages. The use of gamma rayeemitting radiotracers requires involvement of a nuclear medicine physician, and localization requires a handheld gamma probe, which does not permit real-time visualization. Also, preoperative access to the injection site is often required, which in colon cancer patients requires endoscopic injection. Blue dyes cannot be easily seen through fatty tissue and can easily diffuse through the true SLN to second-to third-tier nodes because of their small size.
Recently, optical imaging using near-infrared (NIR) fluorescence has been introduced for real-time visualization of structures during surgery. Advantages of NIR fluorescent (700e900 nm) light include high tissue penetration (several millimeters) and low autofluorescence of tissue in this wavelength region, thereby providing high contrast. To date, indocyanine green is the only clinically available NIR fluorescent tracer and has been used with success for the SNL procedure in several types of cancer including gastrointestinal cancer [10e18]. However, because of relative low fluorescence brightness (quantum yield) and poor SLN retention, indocyanine green is not an ideal SLN tracer [19] . To improve retention of the NIR tracer in the SLN, conjugation of an NIR fluorescent dye, such as IRDdye 800CW, to a larger molecule, such as human serum albumin (HSA; complex: HSA800) is recommended [19] . However, because HSA800 is not yet clinically approved, it can only be used for ex vivo SLN mapping. Previously, our group used HSA800 successfully ex vivo in a feasibility study with patients with colon cancer, and we were able to identify SLNs in all patients [20] . However, in our earlier study we used no blue dye staining because blue dyes might interfere with NIR fluorescence imaging by absorbing the fluorescent light and thereby decreasing the identification rate. At present, blue dye staining is frequently used for the ex vivo SLN procedure, and blue dye staining also provides visual information, which could make it easier to identify and resect SLNs. The aims of this study were to assess the feasibility of the combined use of NIR fluorescence using HSA800 and blue dye staining, and to assess the added value of NIR fluorescence to blue dye staining for SLN mapping in colon cancer patients.
2.
Materials and methods
Preparation of lymphatic tracers
The preparation of HSA800 (IRDye 800CW conjugated to HSA) has been described in detail previously [19] . Briefly, after conjugation of CW800-NHS to albumin, we purified HSA800 using a 7K Zeba Spin Desalting Column (Thermo Scientific, Rockford, IL). The ratio of fluorophore (IRDye 800CW; Li-Cor, Lincoln, NE) to albumin (HSA) was 1. ) in phosphatebuffered saline, with a stock concentration of approximately 600 mmol/L. Peak absorbance and emission of HSA800 were 778 and 795 nm, respectively. To obtain a solution of 50 mmol/L HSA800, we diluted 50 nmol HSA800 in 1 mL patent blue (Bleu Patenté V; Guerbet, Brussels, Belgium) before injection.
Intraoperative NIR imaging system (Mini-FLARE)
We performed clinical SLN mapping using the Mini-FLARE imaging system, which has been described in detail elsewhere [21, 22] . Briefly, the system consists of two wavelengthisolated light sources: a white light source, generating 26,600 lx of 400-to 650-nm light and an NIR light source, generating 7.7 mW/cm 2 of 760-nm light. Color video and NIR fluorescence images are simultaneously acquired and displayed in real time using custom optics and software that separate the color video and NIR fluorescence images. A pseudo-colored (lime green) merged image of the color video and NIR fluorescence images is also displayed. The imaging head is attached to a flexible gooseneck arm, which permits positioning of the imaging head virtually anywhere over the surgical field and at extreme angles.
Clinical trial
We enrolled 22 consecutive patients undergoing surgery with curative intent for colon cancer. Patients with known metastatic disease were excluded. The Leiden University Medical Center Medical Ethics Committee approved this study, which we performed in accordance with the Declaration of Helsinki. All known patients underwent a standard oncological resection including a segmental colonic resection and lymphadenectomy. Tumors were endoscopically marked before surgery when indicated. Directly after resection, the resection specimen was freshly delivered to the Department of Pathology, where the specimen was opened antimesenterically by the pathologist. Subsequently, 1 mL of 50 mmol/L HSA800 diluted in patent blue was injected submucosally circumferentially with a 5-mm margin around the tumor. The injection site was massaged for 5 min, which has been proven sufficient to secure drainage to the SLN in both an in vivo and ex vivo setting [20] . After 5 min, the specimen was inspected using the Mini-FLARE camera system and by visual inspection. We allocated all fluorescent hotspots as SLN and noted whether these nodes were stained blue. The SLNs were separately fixated in 2% buffered formalin for 24 h. After fixation, we harvested all remaining lymph nodes from the specimen and paraffin-embedded all lymph nodes (sentinel and nonsentinel); 4-mm sections were stained with hematoxylin-eosin and subsequently analyzed microscopically for the presence of tumor cells.
Results
We enrolled 22 consecutive patients undergoing surgery for colon cancer. Table 1 lists patient and tumor characteristics. Of these 22 patients, the median age was 69 y (range, 41e88 y); median body mass index was 25 kg/m 2 (range, 20e40 kg/m 2 ). A total of 12 patients were male. Tumor invasion ranged from stage T1 to T4. The median tumor size was 3.7 cm (range, 0.9e9 cm). Four patients had a poorly differentiated tumor, 17 patients had a moderately differentiated tumor, and one had a well-differentiated tumor. Twelve patients received preoperative endoscopic tattooing of the tumor.
After administration of the lymphatic tracer cocktail, at least one SLN was identified in 21 of 22 patients (95%) ( Table 2 ). Sentinel lymph nodes that were located deeper in the mesenteric fat could easily be located by NIR fluorescence but not with the blue dye. After the pathologist subsequent incised the mesentery, in most cases, blue staining of the lymph node was also detected, which provided the pathologist with direct visual support (Fig.) . On average, 3.5 AE 1.9 SLNs/patient were identified. Overall, a total of 77 SLNs were identified, of which 77 (100%) were fluorescent and 70 (91%) were blue (Pearson's correlation coefficient, 0.94). In five patients, fluorescent SLNs were identified (average 1.4 AE 0.5 nodes/patient) that were not stained blue. A total (sentinel and nonsentinel) of 20.5 AE 8.1 nodes were harvested on average from each specimen. Standard histologic analysis showed that five of 22 patients had lymph node metastases. In all but one of these five patients, tumor cells were present in at least one of the SLNs. The false-negative (neither fluorescent nor blue) lymph node was almost completely filled with tumor cells and was easily detected by the pathologist.
Discussion
Nodal status in colon cancer is the most important prognostic factor, which makes it crucial in deciding whether a patient should be considered for adjuvant treatment. Therefore, the main purpose of the SLN procedure in colon cancer patients is the selection of lymph nodes to be assessed by ultrastaging techniques. The current study shows the successful use of NIR fluorescence imaging in combination with blue dye during ex vivo SLN mapping in colon cancer. The NIR fluorescent tracer HSA800 permitted detection of the SLN located deeper into the mesenteric fat. The detection rate of 95% in this study is in concordance with previously reported detection rates in SLN mapping using radiotracers, blue dyes, or a combination of both [9] . This is the first study in which an NIR fluorescent tracer is used in combination with conventional blue dye staining, which is most commonly used as lymphatic tracer, in the ex vivo SLN procedure. Because NIR fluorescence imaging is capable of penetrating millimeters into tissue, it allowed identification of small amounts of the lymphatic tracer deeper into the mesenteric fatty tissue. Moreover, owing to the high spatial resolution of NIR fluorescence, we observed no interference between the fluorescent signal of the injection site and SLNs. We premixed HSA800 with patent blue, and we therefore anticipated staining the same nodes NIR fluorescent and blue. Indeed, there was a high correlation between identification using fluorescence and identification using blue dye staining. However, several fluorescent nodes (9%) did not stain blue. 
Possible explanations could be the high sensitivity of NIR fluorescence imaging, which allows detection of low concentrations of the tracer, and dilution of the blue dye to concentrations not visible with the human eye [23e25] . Because there appears to be little interference of blue dye with NIR fluorescence, in most cases blue staining could be used as complementary direct visual support to assist the pathologist in resecting the SLNs. Preoperative tattooing of the tumor, which is mostly used for tumor localization during laparoscopic surgery, can result in staining of lymph nodes and has been suggested for SLN mapping [26e29]. In the current study, multiple patients received preoperative endoscopic tattooing of the tumor, which resulted in multiple blue colored nodes before the SLN procedure. Because it appeared to be difficult to differentiate between staining by endoscopic tattooing and patent blue staining, the blue dye staining could be less reliable for detecting the first echelon nodes in the current study. Therefore, in patients who received preoperative endoscopic tattooing, the use of NIR fluorescence imaging could overcome these problems.
One false-negative case occurred out of five patients with nodal metastases, which is in concordance with other, earlier studies [9, 30] . In the current study, we identified the SLNs approximately 15 min after injection of HSA800, which adds extra time to the standard workup. In addition, identification of the SLN can be difficult, because not all lymph nodes can be exposed. Identification of SLNs after fixation would allow the pathologist to identify the SLN during routine practice. When SLN detection is performed several hours after injection, optimal retention of the lymphatic tracer in the SLN tracer is essential. However, HSA800 still migrates to higher-echelon lymph nodes, albeit slower than small molecules such as patent blue [19] . When improved retention in the SLN is wanted, nanocolloidal albumin combined with fluorescence can be used, which provides optimal retention in the SLN because of its favorable large hydrodynamic diameter and charge [19,31e33] . Moreover, rather than being only potentially useful for pathologic staging, in vivo SLN mapping has been suggested for patient-tailored extent of surgery [11, 34, 35] . Clinical approval of HSA800 would also allow in vivo NIR fluorescence SLN mapping using this tracer.
This study demonstrated the successful use of a combination of an NIR fluorescence tracer and a conventional blue dye for the ex vivo SLN detection in colon cancer, which can be used as a tool to select the nodes for ultrastaging techniques to identify micrometastases and improve nodal staging. Nearinfrared fluorescence was of added value compared with blue dye staining, because NIR fluorescence allowed detection of additional SLNs and easy detection of SLNs located deeper into the mesenteric fat. Moreover, NIR fluorescence cannot be confused with blue nodal staining resulting from preoperative tattooing of the tumor. 
